Currently out of the existing stock ratings of Yasmeen Rahimi, 254 are a BUY (94.42%), 15 are a HOLD (5.58%).

Yasmeen Rahimi

Work Performance Price Targets & Ratings Chart

Analyst Yasmeen Rahimi works at PIPER SANDLER with a stock forecast success ratio of 24.6% fulfilled within 101.81 days on average.

Yasmeen Rahimi’s has documented 522 price targets and ratings displayed on 42 stocks. The coverage is on Healthcare, Industrials sectors.

Most recent stock forecast was given on DSGN, Design Therapeutics at 07-May-2024.

Wall Street Analyst Yasmeen Rahimi

Analyst best performing recommendations are on MRNA (MODERNA).
The best stock recommendation documented was for MDGL (MADRIGAL PHARMACEUTICALS) at 11/30/2017. The price target of $82 was fulfilled within 6 days with a profit of $31.66 (62.89%) receiving and performance score of 104.82.

Average potential price target upside

ALBO Albireo Pharma ALGS Aligos Therapeutics  ALT Altimmune AMRN Amarin PLC ARCT Arcturus Therapeutics Holdings CBAY Cymabay Therapeu ENTA Enanta Pharmaceuticals ETN Eaton PLC ICPT Intercept Pharmaceuticals IMUX Immunic LMNL Liminal BioSciences MDGL Madrigal Pharmaceuticals MIRM Mirum Pharmaceuticals MRNA Moderna MTNB Matinas BioPharma Holdings NGM NGM Biopharmaceuticals PTGX Protagonist Therapeutics RPHM Reneo Pharmaceuticals SAGE Sage Therapeutic VTYX Ventyx Biosciences VXRT Vaxart ALNA Allena Pharmaceuticals CYTK Cytokinetics LUMO Lumos Pharma PLRX Pliant Therapeutics  AKUS Akouos  DSGN Design Therapeutics RXDX Prometheus Biosciences TNYA Tenaya Therapeutics PRAX Praxis Precision Medicines  CINC CinCor Pharma GOSS Gossamer Bio LXRX Lexicon Pharmaceuticals AXLA Axcella Health GALT Galectin Therapeutics GEMP Gemphire Therapeutics LOGC LogicBio Therapeutics NRBO Neurobo Pharmaceuticals PRTA Prothena plc SVRA Savara IMVT Immunovant  SLNO Soleno Therapeutics

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date

Price targets met ratio

Average potential upside

Average Time (Days) For PT To Be Met

Performance score

Hold

42

$-2.15 (-4.87%)

42

1 years 3 months 3 days ago

0/15 (0%)

$-2.18 (-4.93%)

Buy

42

$-2.15 (-4.87%)

82

1 years 4 months 7 days ago

0/4 (0%)

$-2.1 (-4.76%)

Buy

42

$-2.15 (-4.87%)

68

1 years 4 months 7 days ago

0/3 (0%)

$-2.1 (-4.76%)

Hold

55

1 years 4 months 7 days ago

0/1 (0%)

$36.77 (201.70%)

Hold

42

$-2.15 (-4.87%)

61

1 years 4 months 9 days ago

0/2 (0%)

$-1.85 (-4.22%)

Show more analysts

To gain access for the analyst/ stock price target chart please use a computer

Which stock is Yasmeen Rahimi is most bullish on?

Potential upside of $115.94 has been obtained for MDGL (MADRIGAL PHARMACEUTICALS)

Which stock is Yasmeen Rahimi is most reserved on?

Potential downside of $0.02 has been obtained for CBAY (CYMABAY THERAPEU)

What Year was the first public recommendation made by Yasmeen Rahimi?

On 2017

To continue looking at which analysts cover the stock please register to the basic or advanced membership

What is AnaChart?